biostudies-literatureAmanam INCI NIH HHS5086-5095https://www.ebi.ac.uk/biostudies/studies/S-EPMC7578487biostudies-literatureUnknown12(9)<h4>Background</h4><i>KRAS</i> mutations reported in non-small cell lung cancer (NSCLC) represent a significant percentage of patients diagnosed with NSCLC. However, there still remains no therapeutic option designed to target KRAS. In an era with immunotherapy as a dominant treatment option in metastatic NSCLC, the role of immunotherapy in.<h4>Kras</h4>mutated patients is not clear.<h4>Methods</h4>Eligible patients diagnosed with NSCLC and found to have a <i>KRAS</i> mutation were identified in an institutional lung cancer database. Demographic, clinical, and molecular data was collected and analyzed.<h4>Results</h4>A total of 60 patients were identified for this retrospective analysis. Majority of patients were Caucasian (73%), diagnosed with stage IV (70%) adenocarcinoma (87%), and had Journal of thoracic diseaseRole of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival.PMC7578487P30 CA033572U54 CA209978R01 CA218545Gupta RPharaon RSalgia RMassarelli EKoczywas MAchuthan SAmanam IWang YMambetsariev IReckamp KfalseRole of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival.<h4>Background</h4><i>KRAS</i> mutations reported in non-small cell lung cancer (NSCLC) represent a significant percentage of patients diagnosed with NSCLC. However, there still remains no therapeutic option designed to target KRAS. In an era with immunotherapy as a dominant treatment option in metastatic NSCLC, the role of immunotherapy in.<h4>Kras</h4>mutated patients is not clear.<h4>Methods</h4>Eligible patients diagnosed with NSCLC and found to have a <i>KRAS</i> mutation were identified in an institutional lung cancer database. Demographic, clinical, and molecular data was collected and analyzed.<h4>Results</h4>A total of 60 patients were identified for this retrospective analysis. Majority of patients were Caucasian (73%), diagnosed with stage IV (70%) adenocarcinoma (87%), and had 2020-01-01T00:00:00Z2020 Sep2025-04-25T17:39:00.2Z2025-04-06T06:09:20.506ZS-EPMC75784873314508510.21037/jtd.2020.04.18